MetaCap

Kailera Therapeutics (KLRA) vs Nurix Therapeutics (NRIX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kailera Therapeutics is the larger company by market cap ($1.43 billion vs $1.40 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KLRA-57.62%NRIX-26.61%
+65%-1%-68%
Apr 17, 20261 yearNov 20, 2026
KLRA-57.62%NRIX-26.61%
+60%-3%-66%
Apr 13, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KLRA versus NRIX key metrics
MetricKLRANRIX
Share price$11.02$12.85
Market cap$1.43B$1.40B
1-day change-4.84%-5.55%
YTD return—-32.26%
1-year return—-23.33%
5-year return—-57.25%
P/E ratio (TTM)—5.29
EPS (TTM)$-4.16$2.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$83.98M
Revenue growth (YoY)—+53.95%
Net income (latest FY)—$-264.46M
Operating margin—-340.16%
Net margin—-314.90%
52-week high$28.23$28.23
52-week low$9.76$12.83
Distance from 52-week high-60.96%-54.50%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+290.20%+160.80%
Average volume1.08M2.47M
Shares outstanding129.85M109.25M
Employees145317
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Kailera Therapeutics

KLRA stock →

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees

About Nurix Therapeutics

NRIX stock →

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees

KLRA vs NRIX FAQ

Which is bigger, Kailera Therapeutics or Nurix Therapeutics?

Kailera Therapeutics (KLRA) is larger, with a market capitalization of $1.43B compared with $1.40B for Nurix Therapeutics (NRIX).

Are Kailera Therapeutics and Nurix Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons